Abstract:Abstract:: Neurodegenerative disorders, which include Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS), represent a significant and growing global health challenge. Current therapies predominantly focus on symptom management rather than altering disease progression. In this review, we discuss the major therapeutic strategies in practice for these disorders, highlighting their limitations. For AD, the mainstay treatments are cholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists. For PD, dopamine replacement therapies, including levodopa, are commonly used. HD is managed primarily with symptomatic treatments, and reusable extends survival in ALS. However, none of these therapies halts or substantially slows the neurodegenerative process. In contrast, this review highlights emerging research into bioactive peptides as potential therapeutic agents. These naturally occurring or synthetically designed molecules can interact with specific cellular targets, potentially modulating disease processes. Preclinical studies suggest that bioactive peptides may mitigate oxidative stress, inflammation, and protein misfolding, which are common pathological features in neurodegenerative diseases. Clinical trials using bioactive peptides for neurodegeneration are limited but show promising initial results. For instance, hemiacetal, a γ-secretase inhibitor peptide, has shown potential in AD by reducing amyloid-beta production, though its development was discontinued due to side effects. Despite these advancements, many challenges remain, including identifying optimal peptides, confirming their mechanisms of action, and overcoming obstacles related to their delivery to the brain. Future research should prioritize the discovery and development of novel bioactive peptides and improve our understanding of their pharmacokinetics and pharmacodynamics. Ultimately, this approach may lead to more effective therapies for neurodegenerative disorders, moving beyond symptom management to potentially modify the course of these devastating diseases.

Peptide-based therapeutics targeting genetic disorders

Next-Generation Therapeutics for Rare Genetic Disorders

Peptide therapeutics: Targeting the undruggable space

Peptide Drugs: Current Status and it's Applications in the Treatment of Various Diseases

Exploring the Potential and Challenges of CRISPR Delivery and Therapeutics for Genetic Disease Treatment

Nanotechnology and CRISPR/Cas-Mediated Gene Therapy Strategies: Potential Role for Treating Genetic Disorders

Gene Therapy for Genetic Syndromes: Understanding the Current State to Guide Future Care

Synthetic peptides: promising modalities for the targeting of disease related nucleic acids

Gene therapy for polygenic or complex diseases

Gene Therapy for Monogenic Disorders: Challenges, Strategies, and Perspectives

Advancements in peptide-based therapeutics: Design, synthesis and clinical applications

A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Bioactive Peptides

Recent Advances and Computational Approaches in Peptide Drug Discovery

Peptides as Targeting Agents and Therapeutics: A Brief Overview

Rare genetic disorders in India: Current status, challenges, and CRISPR-based therapy

Finding Chemical Drugs for Genetic Diseases

Gene-based therapeutics for rare genetic neurodevelopmental psychiatric disorders

Pharmacogenomics of Rare and Monogenic Disorders

Gene therapy for CNS disorders: modalities, delivery and translational challenges

Beyond the membrane: Exploring non-viral methods for mitochondrial gene delivery